Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

December 27, 2023

https://www.globenewswire.com/news-release/2023/12/27/2801322/0/en/Beyond-Cancer-Phase-1-Study-Clears-Cohort-1-in-Patients-with-Advanced-Relapsed-or-Refractory-Unresectable-Primary-or-Metastatic-Cutaneous-or-Subcutaneous-Solid-Tumors.html

No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (PPM)

Phase 1 study continues to recruit eligible patients in the next protocol defined cohort of 50,000 ppm in multiple centers in Israel

Read more at globenewswire.com

Related news for (XAIR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.